Nat Burgess, president of Corum Group, a firm involved with software mergers and acquisitions, questioned if Lully would require FDA approval.
According to Boriah, the device is not treating what the FDA would consider a medical condition, and therefore the agency does not recognize it as a medical device or a regulated product."
